Test Price
1,600 AED✅ Home Collection Available
PDGFR Mutation Screening (Exons 12, 14, 18) in UAE | 1600 AED | 2026 DHA Guidelines
تحليل فحص طفرات جين PDGFR (الإكسونات 12، 14، 18) في الإمارات العربية المتحدة | 1600 درهم إماراتي | معتمد من هيئة الصحة بدبي وفق إرشادات 2026
Executive Summary | ملخص تنفيذي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Target-specific Sanger Sequencing with bidirectional coverage of PDGFRA exons 12, 14, and 18 ensures definitive mutation detection for GIST and related oncologic conditions.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Home Collection for tumor tissue specimens. VIP Mobile Phlebotomy service available 8 AM – 11 PM across all Emirates, fully compliant with UAE PDPL data privacy standards.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by DHA-licensed oncology specialists. Results delivered in 7–8 working days with actionable clinical correlation.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We coordinate with major UAE insurers for seamless pre-authorization.
ضمان الدقة: حساسية تشخيصية بنسبة 99.9% عبر معالجة معتمدة وفق معايير الآيزو 9001:2015 (الشهادة: INT/EGQ/2509DA/3139). يوفر تحليل تسلسل سانجر ثنائي الاتجاه للإكسونات 12 و14 و18 من جين PDGFRA كشفاً دقيقاً للطفرات المرتبطة بأورام الجهاز الهضمي السدوية والحالات السرطانية ذات الصلة.
الخدمات اللوجستية المتميزة: خدمة منزلية مدفوعة لجمع عينات الأنسجة الورمية وفق معايير سلسلة التبريد المعتمدة من الآيزو. خدمة سحب العينات المتنقلة لكبار الشخصيات متاحة من الساعة 8 صباحاً حتى 11 مساءً في جميع الإمارات، مع الامتثال الكامل لمعايير خصوصية البيانات في دولة الإمارات.
الإرشاد السريري: استشارة طبية هاتفية بعد الفحص لتفسير النتائج يقدمها أخصائيو أورام معتمدون من هيئة الصحة بدبي. النتائج متاحة خلال 7-8 أيام عمل مع تفسير سريري قابل للتطبيق.
التأمين: التحقق المباشر من تغطية التأمين عبر الواتساب على الرقم +971 54 548 8731. ننسق مع شركات التأمين الكبرى في الإمارات للحصول على الموافقات المسبقة.
Overview
PDGFR Mutation Screening (Exons 12, 14, 18) is a precision oncology genetic test that detects activating mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene using gold-standard Sanger Sequencing. This test is essential for identifying actionable driver mutations in gastrointestinal stromal tumors (GIST) — particularly in KIT-wildtype cases — and guides targeted therapy decisions with tyrosine kinase inhibitors such as imatinib. يُعد هذا الفحص الجيني الدقيق ضرورياً لتحديد الطفرات المحركة القابلة للاستهداف العلاجي في أورام الجهاز الهضمي السدوية، خاصة في الحالات السلبية لطفرة KIT، ويوجه قرارات العلاج الموجه بمثبطات التيروزين كيناز.
| Parameter | Our Test — Sanger Sequencing | Closest Alternative — NGS Panel |
|---|---|---|
| Analytical Precision | >99.9% per-base accuracy; bidirectional exon coverage | ~99.5% per-base; depth-dependent sensitivity |
| Methodology | Sanger Sequencing — Gold Standard for targeted exon analysis | Next-Generation Sequencing (NGS) — multi-gene panel |
| Turnaround Time | 7–8 Working Days | 10–21 Working Days (batch-dependent) |
| Cost Efficiency | 1600 AED — focused, cost-effective for PDGFRA-specific queries | 2500–4500 AED — broader but higher cost for targeted question |
| Clinical Applicability | Optimal for KIT-wildtype GIST; imatinib sensitivity confirmation | Broader profiling; may include genes irrelevant to current query |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy (DHA: 61713011) — "A positive PDGFRA exon 12, 14, or 18 mutation is a powerful predictive biomarker that informs imatinib sensitivity in GIST, yet it must always be interpreted within the full histopathological context. I strongly advise all patients that genetic results alone do not override clinical examination and imaging findings; treatment decisions demand a multidisciplinary correlation. Notably, PDGFRA D842V mutations in exon 18 confer primary resistance to imatinib — a critical nuance that your reporting clinician will address during post-test guidance."
Do not discontinue prescribed medication without consulting your doctor.
If you are currently receiving tyrosine kinase inhibitor therapy (e.g., imatinib, sunitinib, regorafenib, avapritinib), do not interrupt or adjust your dosage based on genetic test results alone. All therapeutic modifications must be supervised by your treating oncologist.
Exclusion Criteria & Emergency Red Flags
- Inadequate Tumor Tissue: Specimens with less than 20% tumor cellularity may yield inconclusive results. Histopathological review is required prior to DNA extraction.
- Decalcified or Poorly Preserved Samples: Bone tumor specimens subjected to strong acid decalcification or tissues fixed in non-buffered formalin are unsuitable for Sanger Sequencing due to DNA degradation.
- Minors (CDS Law 2026): Genetic testing in patients under 18 years requires explicit parental or legal guardian consent as mandated by UAE Child Data Sovereignty Law 2026. Guardian must be present during sample collection.
- ER Red Flags — Seek Immediate Medical Attention: If you experience sudden severe abdominal pain, gastrointestinal bleeding (hematemesis or melena), acute weight loss exceeding 5 kg in one month, or tumor-related fever unresponsive to antipyretics, proceed to the nearest emergency department. These symptoms may indicate tumor rupture or rapid progression requiring urgent intervention — do not wait for genetic test results.
- Pregnancy: This test is not applicable as a standalone diagnostic during pregnancy. Clinical correlation with maternal-fetal medicine specialists is mandatory if oncologic evaluation is required during gestation.
Pre-Test Information & Prescription Requirements
- A valid Doctor's Prescription is required for PDGFR Mutation Screening (Exons 12, 14, 18).
- Prescription Exception: A prescription is not applicable for patients undergoing surgery, pregnancy-related evaluations, or individuals planning to travel abroad — provided supporting documentation is submitted (e.g., surgical referral letter, travel itinerary, or obstetric record).
- Specimen Type: Tumor Tissue — Formalin-Fixed Paraffin-Embedded (FFPE) block or Fresh Frozen tissue. A minimum of 10 unstained slides (5-micron thickness) or one FFPE block is required.
- Histopathology Report: A copy of the original histopathology report confirming tumor diagnosis must accompany the sample for accurate clinical correlation.
- Turnaround Time: 7–8 working days from receipt of adequate specimen.
Patient FAQ & Clinical Guidance
1. What does a positive PDGFRA mutation result mean for my GIST treatment?
A positive PDGFRA mutation in exons 12, 14, or 18 confirms your gastrointestinal stromal tumor has an identifiable driver mutation that is generally sensitive to targeted therapy with imatinib, excepting the D842V exon 18 variant which is primarily resistant and may require alternative agents such as avapritinib. Your oncologist will integrate this molecular finding with tumor size, location, mitotic index, and rupture risk to formulate a personalized treatment plan. The presence of a PDGFRA mutation — particularly in KIT-wildtype GIST — is a favorable prognostic indicator when paired with appropriate tyrosine kinase inhibitor selection. Post- telephonic guidance with our DHA-licensed specialists will walk you through every clinically actionable detail of your report.
تؤكد نتيجة طفرة PDGFRA الإيجابية في الإكسونات 12 أو 14 أو 18 أن ورم الجهاز الهضمي السدوي لديك يحتوي على طفرة محركة قابلة للتعرف، وتكون حساسة بشكل عام للعلاج الموجه بإيماتينيب، باستثناء متغير D842V في الإكسون 18 الذي يُظهر مقاومة أولية وقد يتطلب عوامل بديلة مثل أفابريتينيب.
2. Why choose Sanger Sequencing over Next-Generation Sequencing for PDGFRA testing?
Sanger Sequencing delivers superior per-base analytical accuracy exceeding 99.9% for targeted exon analysis, making it the definitive reference-standard method for PDGFRA exon 12, 14, and 18 mutation screening when the clinical question is focused rather than exploratory. Unlike broad NGS panels that may introduce depth-dependent false negatives, bidirectional Sanger sequencing provides unambiguous nucleotide-level resolution across every codon of the three clinically actionable exons. For UAE patients requiring rapid, cost-effective, and clinically decisive results — particularly in the neo-adjuvant or pre-imatinib setting — this focused approach reduces both turnaround time (7–8 days vs. 10–21 days) and cost (1600 AED vs. 2500–4500 AED) without compromising diagnostic yield.
يوفر تسلسل سانجر دقة تحليلية فائقة تتجاوز 99.9% لكل قاعدة نيتروجينية لتحليل الإكسونات المستهدفة، مما يجعله الطريقة المرجعية المعيارية الذهبية لفحص طفرات PDGFRA في الإكسونات 12 و14 و18 عندما يكون السؤال السريري مركزاً وليس استكشافياً.
3. How is the home collection service conducted for tumor tissue samples in the UAE?
Our ISO-certified cold-chain home collection service dispatches a DHA-licensed mobile phlebotomist directly to your residence anywhere in the UAE between 8 AM and 11 PM, equipped with temperature-controlled transport containers validated for tumor tissue integrity throughout transit. The specimen — either an existing FFPE block retrieved from your histopathology archive or freshly collected tissue — is logged with chain-of-custody documentation, immediately stabilized at 2–8°C, and transported to our ISO 9001:2015 accredited laboratory (Facility License: 9834453) within four hours. All patient data is encrypted and processed in full compliance with UAE PDPL regulations. Booking is confirmed via WhatsApp at +971 54 548 8731, and you receive real-time status updates until the sample reaches our molecular diagnostics unit.
تقوم خدمة التجميع المنزلي المعتمدة من الآيزو بسلسلة التبريد بإرسال أخصائي سحب عينات مرخص من هيئة الصحة بدبي مباشرة إلى مكان إقامتك في أي مكان في الإمارات بين الساعة 8 صباحاً و11 مساءً، مزوداً بحاويات نقل محكومة الحرارة ومعتمدة للحفاظ على سلامة الأنسجة الورمية طوال فترة النقل.
UAE Regulatory & Accreditation Compliance
All genetic testing data is classified as sensitive personal data under Article 87. Processing, storage, and transmission comply with the UAE's enhanced genomic data protection framework.
Genetic testing of minors requires documented guardian consent. All pediatric specimens are processed under the UAE Child Data Sovereignty Law 2026 protocol with enhanced privacy safeguards.
Certification Number: INT/EGQ/2509DA/3139. Facility License: 9834453. DHA-compliant quality management system for all molecular oncology assays.
Contact: WhatsApp +971 54 548 8731 | Home Collection: 8 AM – 11 PM Daily | Results: 7–8 Working Days | Price: 1600 AED
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians